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Abstract
Background: Regenerative and anti-inflammatory effects on tendinopathies have been attributed to blood-derived
biologicals. To date the evidence for the efficacy of autologous platelet-rich plasma (PRP) treatment of naturally
occurring equine tendinopathies is limited. The purpose of this placebo-controlled clinical trial was to describe the
effect of a single treatment of equine superficial digital flexor tendon (SDFT) disease with PRP on clinical and
ultrasonographic parameters. Twenty horses with naturally occurring tendinopathies of forelimb SDFTs were
randomly assigned to the PRP-treated group (n = 10) or control group (n = 10) after clinical and ultrasonographic
examination. The SDFTs received an intralesional treatment with autologous PRP or were injected with saline,
respectively (day 0). All horses participated in a standardized exercise programme and were re-examined clinically,
with B-mode ultrasonography (5 times at regular intervals) and ultrasound tissue characterization (week 12 and 24
after treatment) until week 24. Long-term performance was estimated via telephone inquiry.
Results: Compared to day 0, lameness decreased significantly by week 8 after treatment with PRP and by week 12
in the control group. Ultrasonographically there was no difference in the summarized cross sectional area between
the groups at any time point. Ultrasound tissue characterization showed that echo types representing disorganized
matrix decreased significantly throughout the observation period in the PRP-treated group. Echo type II,
representing discontinuous fascicles, not yet aligned into lines of stress was significantly higher 24 weeks after PRP
treatment. Eighty percent of the PRP treated horses reached their previous or a higher level of performance after
12 months compared to 50 % in the CG. After 24 months these proportions were 60 % and 50 %, respectively.
Conclusions: A single intralesional treatment with PRP up to 8 weeks after onset of clinical signs of tendinopathy
contributes to an earlier reduction of lameness compared to saline treatment and to an advanced organization of
repair tissue as the fibrillar matrix is getting organized into fascicles while remodelling continues. Long term, PRP
treatment has the potential to increase the number of horses reaching their previous level of performance. Earlier
treatment of tendinopathy with PRP should be considered to enhance these effects.
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Background
Tendinopathy of the superficial digital flexor tendon
(SDFT) is a common injury in Thoroughbred racehorses
and other horse breeds [1, 2] and is regarded as a career-
limiting disease [3]. Clinical injury is mostly strain induced
and characterized by chronic degeneration after repetitive
microtrauma in sport horses [3]. Tendinopathy may also be
caused by a single external percutaneous trauma, such as a
kick [4]. A plethora of substrates for intralesional injection
with a potentially regenerative effect on tendinopathy are
currently under investigation [5, 6]. Among these are plate-
let concentrates such as platelet-rich plasma (PRP) [7].
Concentrated platelets release numerous cytokines
and growth factors, e.g. platelet derived growth factor-
BB (PDGF-BB), transforming growth factor-ß (TGF-ß)
and vascular endothelial growth factor. These factors are
known to exercise specific actions during tendon healing
(for review see Docheva et al. 2015) [6, 8]. PDGF-BB,
e.g. stimulates tendon healing depending on its concen-
tration [9]. PRP has been shown to enhance tenocyte
proliferation [10], collagen and matrix synthesis [11, 12]
and to influence vascular density [13].
PRP has shown significant enhancing effects on ten-
don healing such as improved biomechanical properties
in a surgical model of equine SDFT lesions [13, 14] and
is increasingly used for intralesional treatment of tendi-
nopathy and desmopathy in humans [15] and horses
[16–19] in clinical practice. However, the efficacy of PRP
treatment on tendinopathy is seen controversially in
human studies: In a randomized controlled clinical trial
on chronic human Achilles tendinopathy intralesional
PRP treatment showed no beneficial effects compared to
saline injection [20]. These results are supported by a
further randomized controlled study demonstrating no
differences in elasticity modulus of PRP- versus non-
treated Achilles tendons [21]. In other clinical studies
without control groups PRP treatment of chronic
Achilles and patellar tendinopathy significantly improved
symptoms and function [22, 23]. To the best of our
knowledge the effect of a single intralesional treatment
with autologous PRP on equine naturally occurring SDF
tendinopathy has not been documented in a prospective
randomized placebo-controlled clinical study with long
term follow-up in the literature to date (for review see
Brossi et al. 2015) [18].
Autologous platelet concentrates are prepared by centri-
fugation or by gravitational cellular filtration [24]. Blood
samples from different horses and the use of different non-
standardised and commercial kits for the preparation of
PRP lead to differences in the platelet, leucocyte and
growth factor content [24]. Different breed, age and gender
influences growth factor and cytokine release of platelets
and leucocytes [25, 26]. The optimal platelet and leucocyte
contents in PRP are a point of debate. Recent investiga-
tions have shown that a moderate increase in platelets
seems to enhance equine tenocyte growth and collagen
synthesis more effective than high platelet concentrations
[27, 28]. High leucocyte counts in PRP were observed to
enhance the inflammatory reaction in rabbit tendons [29].
The process of tendon healing is mainly divided into
three phases which merge into each other: The acute in-
flammatory phase (<10−14 days) is characterized by
phagocytosis of disrupted tendon tissue and demarcation
of injured tendon tissue. A fibroproliferative callus is
formed during the proliferative phase (4–45 days), while
collagen fibrils are organised into tendon bundles during
the phase remodelling (45–120 days; < 3 months) which
may be divided into an consolidation (earlier) and
maturation (later) phase [3, 30].
A critical parameter to determine the success of tendi-
nopathy treatment is functionality, which can be charac-
terized by lameness evaluation, long term recurrence
rate [2, 31] and biomechanical testing [32]. To deter-
mine the quality of repair tissue tendon needle biopsies
have been used successfully [33]. Ultrasound based
modalities such as B-mode ultrasonography [34] and
colour Doppler ultrasonography [13] have been estab-
lished to monitor the process of tendon healing non-
invasively. However, B-mode ultrasonography has several
limitations, e.g. lack of axial information, operator-
dependence, influence of ultrasound beam angle and
limited resolution that impair its sensitivity [35, 36].
Geburek et al. BMC Veterinary Research  (2016) 12:191 Page 2 of 16
Ultrasound tissue characterization (UTC) is a new tech-
nique to quantify tendon integrity based on a computer-
ized analysis of the stability of echo-patterns in
contiguous US images [37, 38]. Based on the echo-
pattern stability, 4 different echo types can be discrimi-
nated, with histo-morphology of tendon specimen as ref-
erence test [37, 39]. Ultrasound tissue characterization
has been shown a viable diagnostic tool to monitor ex-
perimental tendinopathy in horses [39–42] and is in-
creasingly used for the quantification of Achilles and
patellar tendon integrity in humans [43, 44].
Aim of current study
The aim of the present study was to support the hypoth-
esis that a single intralesional injection of autologous
PRP into SDFT lesions up to 8 weeks after clinical onset
(1) has a clinically detectable effect and (2) leads to im-
proved ultrasonographic parameters (3) influences long
term functionality.
Methods
Inclusion criteria for client-owned adult horses was an an-
amnesis of clinical signs of uni- or bilateral SDFT disease
in front limbs for up to 8 weeks (56 days) prior to the
presentation at the Equine Clinic of the University of Vet-
erinary Medicine, Hannover, Foundation, or to collaborat-
ing veterinarians. Horses were only included if the clients
agreed to the study design and tendons had not received
intralesional injections before. Twenty horses with a mean
age of 8.46 years (range: 4–21 years) and a mean body-
weight of 548 kg (range: 398–644 kg) met the inclusion
criteria (Table 1). Horses were randomly assigned to the
group treated with PRP (PRPG, n = 10) or the control
group (CG, n = 10). The PRPG comprised 7 Warmbloods
(70 %), 1 Haflinger (10 %), 1 New Forest Pony (10 %) and
one Pinto (10 %). Eight Warmbloods (80 %), 1 Andalusian
(10 %) and 1 German Riding Pony (10 %) were included in
the CG (Table 1). The study was carried out between 2012
and 2014.
Clinical examination
All horses were examined clinically on the day of first
presentation (day 0). This examination included assess-
ment of lameness (5 grade score) [45] and palpable signs
of inflammation scored semi-quantitatively by palpation
(skin surface temperature in the palmar metacarpal region,
sensitivity of the SDFT to palpation: 0 = no abnormality, 1
=mild abnormality, 2 =moderate abnormality, and 3 = se-
vere abnormality) [46]. All clinical examinations through-
out the study were performed by the same person (M.G.).
B-mode ultrasonography
Horses were sedated with romifidine (0.04–0.08 mg/kg
intravenously [IV]) and butorphanol (0.01 mg/kg [IV]).
Injured and contralateral SDFTs were examined by one
examiner with B-mode ultrasound on day 0 in a trans-
verse and longitudinal fashion with a linear 6–15 MHz
linear scanner (Logiq E9, GE Healthcare, Wauwatosa,
WI, USA) using a standoff (GE 12 L 2302652 Standoff,
Veterinary Sales & Service Inc., Stuart, USA), according
to the seven zone designations as previously described
[47, 48]. Settings were 13 MHz, gain 52, depth 25 mm,
focus position 15 mm. Images were stored digitally and
analysed retrospectively with a DICOM workstation pro-
gram (easyVET®, IFS Informationssysteme, Hannover,
Germany) by one observer (M.G.) being unaware of the
treatment modality. The following parameters were eval-
uated to determine the degree- and time-related changes
of the lesions: maximal injury zone (MIZ), summarized
cross sectional areas of tendon (total cross-sectional
area, T-CSA). Echogenicity and fibre alignment were
graded semiquantitatively at each zone and the scores
for all levels were summarized (total echo score = TES,
total fibre alignment score = T-FAS). Echogenicity was
assigned to 0 (normoechoic), 1 (hypoechoic), 2 (mixed
echogenicity), and 3 (anechoic), and fibre alignment was
graded according to the estimated percentage of parallel
fibres in the lesion: 0 (>75 %), 1 (50–74 %), 2 (25–49 %),
and 3 (<25 %) [34, 48].
Ultrasound tissue characterization (UTC)
Injured SDFTs were scanned with the commercially
available ultrasound tissue characterization (UTC) unit
(UTC scan unit, configuration 2011, UTC Imaging B.V.,
6171 GD Stein, Netherlands) on day 0. It consisted of 5–
10 MHz linear transducer (LA T Transducer, Terason
Ultrasound, Teratech Corporation, Burlington, USA)
which was fixed in transverse position, perpendicular to
the integrated stand-off, in a motorized tracking device
(UTC scan unit, configuration 2011, Fa. UTC Imaging
B.V., GD Stein, Netherlands) that moves the transducer
automatically along the tendon. Within the UTC proto-
col the instrumental settings for the SDFT were selected
which facilitated standard settings like persistence,
depth, focal point, gain, TGC-curve, to be used for all
scans. During scanning, transverse US images were cap-
tured at regular distances of 0.2 mm over a distance of
12 cm and stored real-time in a high-capacity laptop
computer (MacBook Pro® 17“, Apple, Cupertino, USA).
Compilation of these images created a 3-D block of US
information that was used for quantification of stability
of contiguous echo-patterns. Based on the echo-pattern
stability, 4 different echo-types were discriminated, with
histo-morphology of tendon specimen as reference test:
type I, generated by intact and fully aligned fascicles
(secondary collagen bundles); type II, generated by
discontinuous, waving, not (yet) aligned and/or swollen
fascicles (secondary collagen bundles); type III, generated
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by a mainly fibrillar matrix (collagen fibrils not/no yet
organized into fascicles) and type IV, generated by a
mainly amorphous matrix and/or fluid [37, 39].
Scanning for UTC was performed in standing, fully
sedated horses while all limbs were weightbearing. As
the UTC device allows to scan a metacarpal segment of
approximately 12 cm, the device was applied to the
metacarpal area in a way during the initial exam that the
zone of maximal injury (MIZ) was centered in the
middle of the standoff. The distance from the most
prominent point of the accessory carpal bone to the
proximally located edge of the standoff was measured
and recorded to ensure that the same segment would be
scanned during following UTC scans. Additionally this
point was marked in the horse’s latero-palmar metacarpal
haircoat with a shaving blade. A corresponding segment
of the SDFT of the opposite front limb was scanned in the
same manner.
With the help of the software, the stability of the echo
pattern of corresponding pixels over 9 contiguous trans-
verse images was analysed by UTC algorithms. Images
were controlled for movement artifacts and repeated if
necessary. Data sets were stored digitally on the
computer until final analysis.
A single scan of each tendon was analyzed retrospect-
ively with the analyzing-software (UTC2011® Analyser
V1.0.1, Fa. UTC Imaging, 6171 GD Stein, The
Netherlands) by one observer (M.G.) being blinded to
Table 1 Signalement, clinical history, diagnostic data and treatment of 20 horses with SDFT lesions













1 Hannoverian 4 G Dressage 2 Unknown LF 2a, lat Marginal
2 Hannoverian 8 M Dressage 1 Training LF 3a, palm Marginal
3 Haflinger 21 G Trained horse 2 Pasture
turnout
LF 2b Diffuse
4 Trakehner 5 S Dressage 4 Pasture
turnout
RF 3b, med Marginal
5 Oldenburger 16 G Police horse 2 Ride RF 2b Diffuse
6 Rhenish
Warmblood
13 M Dressage 2 Unknown RF 3a Core
7 Hannoverian 6 M Dressage 2 Running free LF 2b, palm Marginal
8 New Forest Pony 13 G Pleasure 3 Pasture
turnout
LF 2b Diffuse
9 Hannoverian 11 G Eventing 8 Training RF 3a Core
10 Pinto 20 G Pleasure 7 Unknown LF 2b, lat Marginal
∅ 11.7
Control group
1 Oldenburger 9 M Jumping 4 Jumping LF 3a, lat Marginal
2 Hannoverian 5 G Dressage 6 Unknown LF 3a, med Marginal
3 Andalusian 18 M Pleasure 3 Pasture
turnout
LF 2b Diffuse
4 Hannoverian 15 M Dressage,
jumping
2 Training LF 2b, med Marginal
5 German Riding
Pony
9 M Jumping 1 Jumping LF 3a, lat Marginal
6 Hannoverian 12 G Police horse 2 Running free RF 1b, lat Marginal
7 Hannoverian 20 M Pleasure 2 Unknown RF 2a diffuse
8 Rhenish
Warmblood
7 G Eventing 2 Training LF 3a Core
9 Hannoverian 10 G Eventing 6 Jumping LF 2b, lat Marginal
10 Hannoverian 6 G Pleasure 4 Unknown RF 3a Diffuse
∅ 11.1
SDFT superficial digital fexor tendon, w week(s), y years, S stallion, M mare, G gelding, LF left front, RF right front, PRP-group SDFT treated with intralesional
injection of platelet-rich plasma, Control group SDFT treated with intralesional saline injection, lat lateral, med medial, palm palmar, ∅ mean
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the treatment modality: A 6 cm long tendon segment was
defined from 3 cm distally and proximally to the MIZ, re-
spectively, on the colour coded longitudinal image pro-
duced during the first examination (day 0). Within this
segment, the entire cross sectional area of the SDFT was
analyzed using every 15th consecutive transverse image,
i.e. every 3 mm. Ratios of echo types were analyzed quan-
titatively as fractions of the entire cross sectional area and
mean values for the proportion of each type were calcu-
lated. The distance from the center of MIZ to the prox-
imal end of the scan was measured to retrieve the MIZ
and thereby the segment to be analyzed in control scans
during the remaining examination period.
Preparation of PRP, Intralesional treatment, controlled
exercise and follow-up examinations
Fiftyfour millilitres of autologous blood were collected
by a single venipuncture of one jugular vein into a 60 ml
syringe preloaded with 6 ml of the anticoagulant acid
citrate dextrose (ACD-A). Approximately 5 ml of whole
blood was aspirated into a tube containing EDTA
(Vacuette®, Greiner Bio-One International AG, Krems-
münster, Austria) for later cell counts. To ensure that
the whole blood and anticoagulant homogenously mix,
the syringe was inverted gently 4 times. The content was
transferred aseptically into bag A of a commercially
available PRP preparation system (Osteokine®, Orthogen,
Düsseldorf, Germany). The bag system was inserted in a
swingout bucket of a centrifuge (Universal 300®, Andreas
Hettich GmbH & Co. KG, Tuttlingen, Germany) and a
corresponding swingout bucket was filled with a coun-
terweight. According to the manufacturer’s instruction
the first centrifugation step was performed at a relative
centrifugation force of 900 g for 3 min. The plasma in-
cluding the buffy coat was transferred via the connecting
tube to bag B by gently rolling the bottom of bag A up-
wards with a clamp. After closing the ports between bag
A and B the system was centrifugated for 10 min at a
relative centrifugation force of 1470 g. The supernatant
platelet poor plasma (PPP) was aspirated via the with-
drawal port. The remaining pellet of platelets and re-
sidual erythrocytes was resuspended by reinjecting a
volume of 3 ml of PPP into bag B. The resulting PRP
was completely aspirated from bag B which led to a vol-
ume of 4 ml. An aliquot of 1 ml PRP was transferred to
a tube containing EDTA (Vacuette®, Greiner Bio-One
International AG, Kremsmünster, Austria), while the
remaing 3 ml were used for intralesional injection. Plate-
let- and leucocyte content was determined from whole
blood and PRP with an automated cell counter (KX-
21 N®, Sysmex, Norderstedt, Germany).
Horses were sedated for the intralesional injections
with detomidine hydrochlorid (0.01–0.03 mg/kg [IV])
and butorphanol (0.04–0.05 mg/kg [IV]), and the medial
and lateral palmar nerves were anaesthetized 2 cm distal
to the carpometacarpal joints with 2,5 ml of a 2 %
mepivacain solution, respectively.
After aseptic preparation of the skin, superficial digital
tendon lesions were injected under sonographic
guidance from the lateral aspect of the tendon perpen-
dicularly to its long axis directly into the most
hypoechoic areas through a 22G (∅ 0.7 mm, 30 mm)
canula (BD MicrolanceTM 3, Becton Dickinson S.A.,
Fraga, Huesca, Spain) while the limb was weight-
bearing. SDFTs allocated to the PRPG received an intra-
lesional treatment of 3 ml into the tendon defect (day 0).
Tendons in the CG were injected intralesionally with 3 ml
0,9 % sterile saline solution (Isotone Kochsalzlösung
0,9 %®, B. Braun Melsungen, Melsungen, Germany). The
volume of PRP or saline was equally distributed to 3 sites.
The first injection was performed at the maximal injury
zone. Further injection sites were 1–2 cm distally and
proximally to the first injection. A padded distal limb
bandage was applied and left in place during a period of
3 days box rest in all horses. The contralateral SDFT was
not injected. All front hooves of all horses were shod with
a closed horse shoe with a straight bar [49]. All horses
participated in a gradually increasing exercise programme
adapted from Bosch et al. [14]. Depending on the
anamnestically reported duration of clinical SDF tendino-
pathy of less than 4 weeks or 5–8 weeks, horses were
either given box rest for another 4 weeks or commenced
with handwalking for 10 min, respectively (Table 2). The
horses were re-examined clinically and with B-mode ultra-
sonography at 4, 8, 12, 18 and 24 weeks after injection.
Ultrasound tissue characterization was repeated 12 and
24 weeks after treatment.
All owners were asked about the performance of their
horses via telephone inquiry 12 and 24 months after
treatment according to the following categories: reached
previous or higher level of performance; was ridden at a
lower level of performance; was retired; died.
Statistical analysis
Analysis of data was performed using SAS® Version 9.3
(SAS Institute, Cary, NC, USA). The level of significance
Table 2 Gradually increasing exercise programme adapted from
Bosch et al. [14] and modified
Exercise/day Period
Box rest 4 weeks
10 min walk Weeks 5–8
20 min walk + 2 × 3 min trot Weeks 9–12
30 min walk + 15 min trot Weeks 13–15
30 min walk + 15 min trot + 3 × 1 min gallop Weeks 16–18
35 min walk + 15 min trot + 3 × 5 min gallop Weeks 19–24
minminutes
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was set at p < 0.05. All values in the graphs are expressed
as arithmetic mean values with standard error (X ± SEM).
The assumption of normality was tested using the
Kolmogorov-Smirnov test and visual assessment of qq-
plots of model residuals. In the case of rejection of normal
distribution, distribution-free nonparametric methods
were applied. Fisher’s exact test was applied by evaluation
of contingency tables to test the differences between
groups (PRP-treated group and control group) on each
examination day with regard to the parameters degree of
lameness, sensitivity to palpation and skin surface
temperature. To work out the differences of these parame-
ters within a group between examination days, non-
adjusted p-values were used provided that the global test
was significant (p < 0,05) or showed a tendency to signifi-
cance (p = 0,05 - 1). The influence of the groups and time
points on the ultrasonongraphic parameters (T-CSA,
T-FAS and TES) was tested using a two-way analysis of
variance for independent samples (groups) and repeated
measurements (time points), followed by the Tukey post
hoc test for multiple pairwise comparisons. P-values were
used in terms of comparison to assess differences of
parameters between individual days of examination within
a group and vice versa, and to determine the differences be-




On day 0, 60 % (n = 6) of the horses included in the PRPG
were lame. Fifty percent (n = 5) of the control horses
showed a lameness. In all horses it was the lame limb
where tendinopathy was diagnosed. After 24 weeks 2
horses in the PRPG were still lame and 1 horse in the CG
was lame. The mean degree of lameness did not differ
between groups on any day of examination. Compared to
day 0 lameness decreased significantly by week 8 after
treatment within the PRPG (p = 0.011) and it decreased
significantly by week 12 in the CG (p = 0.014) (Fig. 1a).
Clinical signs of inflammation
No statistically significant differences between the two
groups with regard to scores for sensitivity to palpation
and skin surface temperature were observed on day 0
and during the entire observation period (Fig. 1b, c).
Within the PRPG scores for sensitivity to palpation of
the SDFTs decreased significantly for the first time be-
tween week 4 and week 8 (p = 0.003) and in the CG be-
tween day 0 and week 4 (p = 0.02). From week 12 until
the end of the observation period no painful reaction
could be elicited in all horses (Fig. 1b). Scores for skin
surface temperature (Fig. 1c) decreased significantly be-
tween day 0 and week 4 (p = 0.001) in the PRPG. Within
the CG it took until week 8 that skin surface
temperature decreased significantly (p = 0.001). From
week 8 onwards scores for this parameter remained at a
low level up to 24 weeks in both groups.
Fig. 1 Clinical findings after PRP and saline treatment of SDFT
lesions over time. a Degree of lameness. b Scores for sensitivity to
palpation. c Scores for skin surface temperature in the palmar
metacarpal region. Mean ± SE; global test for PRPG and CG p < 0.001;
Different letters (PRP normal and control italic) indicate significant
differences (p < 0.05) within groups; PRPG = PRP-group: n = 10 limbs,
SDFTs treated intralesionally with PRP; CG = control group: n = 10
limbs, SDFTs treated intralesionally with saline; black arrow = day 0:
diagnosis, intralesional injection of PRP/saline; PRP = platelet-rich
plasma; w = weeks; SDFT = superficial digital flexor tendon
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B-mode ultrasonography
The horses included were presented with core lesions
(3 horses), marginal lesions (11 limbs) or diffuse lesions
(6 limbs) of the SDFT (Table 1). Control horses no. 3
and 7 had ultrasonographic signs of scarring of the
SDFT in the contralateral non-lame limb on day 0. The
MIZ of most lesions was located in zones 2b and 3a
(80 % of horses in PRPG and CG, respectively),
followed by zone 2a (10 % of horses in PRPG and CG,
respectively), and zones 1b (10 % of horses in PRPG)
and 3b (10 % of horses CG), respectively). There was
no difference in T-CSA between the groups at any time
point (Fig. 2a). Compared to the contralateral SDFT,
T-CSA was significantly higher in PRP treated and in
control limbs than in the respective contralateral limbs
during the whole observation period (p < 0.05). Within
the PRP group T-CSA was significantly higher (p = 0.024)
only in week 4 as compared to week 18 (Fig. 2a). TES was
significantly higher in the PRPG than in the CG at weeks 4,
8, 12 and 24 (p= 0.0397, p= 0.0069, p= 0.00297, p= 0.0424)
(Fig. 2b); and T-FAS was significantly higher in the PRPG
than in the CG at weeks 4, 8 and 12 (p= 0.0387, p= 0.0140,
p= 0.0283) (Fig. 2c). Regarding the progression of TES and
T-FAS they decreased significantly between day 0 and week
12 in the PRPG (TES: p= 0.002; T-FAS: p= 0.001) and
between day 0 and week 8 the CG (TES: p < 0.001, T-FAS:
p= 0.023) (Fig. 2b, c).
Ultrasound tissue characterization
The percentages of echo types I, III, IV (Fig. 3a, c, d),
combined types I + II and combined types III + IV (Fig. 4)
did not differ between groups at any time point. The per-
centage of echo type II was significantly higher (p= 0.0492)
in the PRPG than in the CG at the end of the observation
period (Fig. 3b).
In the PRPG percentages of combined type I + II pixels
representing fascicular structures increased significantly
between week 12 and 24 (p = 0.009) (Fig. 4a). Combined
types III + IV percentages representing disorganized
matrix decreased significantly between day 0 and week 12
(p < 0.001) and again between weeks 12 and 24 (p = 0.024)
in the PRPG (Fig. 4b). In the CG both, combined type I +
II and combined type III + IV did not change throughout
the observation period (p > 0.05) (Fig. 4).
In the CG echo type I, i.e. intact and fully aligned
fascicles increased significantly between day 0 and week
12 (p = 0.001) and after PRP treatment between week 12
and 24 (p = 0.012) (Fig. 3a). Echo type III representing
mainly fibrillary matrix decreased significantly in both
groups between day 0 and week 12 (p < 0.001). It further
decreased significantly between week 12 and 24 in the
PRPG (p = 0.006) while it remained on the same level in
the CG (Fig. 3c). The percentage of echo type IV, i.e.
amorphous matrix/fluid decreased siginificantly between
day 0 and week 12 in the PRPG (p < 0.001). In the CG
this type remained on the same level throughout the
whole observation period (Fig. 3d).
Concentration of platelets and leucocytes
The mean number of platelets was 157.3 ± 35.9 × 103/μl
in whole blood and 892.37 ± 364.7 × 103/μl in PRP.
Leucocyte content was 7.8 ± 1.5 × 103/μl in whole blood
and 14.1 ± 7.0 × 103/μl in PRP. Compared to whole blood
platelets and leucocytes were concentrated significantly
by factor 5.67 (p = 0.0001) and 1.81 (p = 0.0139), respect-
ively in PRP.
Long-term follow-up
One horse allocated to the PRPG and one control horse
developed recurrence of tendon injury in the treated
limb within 2 years post diagnosis. One PRP treated
horse developed tendinopathy in the SDFT of the
contralateral front limb. Twelve months after treatment
80 % (8/10) of the horses allocated to the PRPG
performed at the previous or at a higher level while this
was the case in 50 % (5/10) of the control horses.
Twenty-four months after treatment 60 % (6/10) were
still ridden at the previous or higher level of perform-
ance in the PRPG while this was the case in 50 % (5/10)
of the control horses. Horses that were ridden at a lower
level of performance made up 10 % (1/10) of the PRP
treated horses after 12 months and 20 % (2/10) after
24 months. In the CG 40 % (4/10) of the horses per-
formed at a lower level after 12 months and 20 % (2/10)
after 24 months. One horse included in the PRPG was
retired within 12 months while one control horse was
retired between 12 and 24 months after treatment. One
PRP treated horse died of reasons unrelated to
tendinopathy between 12 and 24 months and one control
horse died within 12 months after treatment. Long term
outcome did not differ significantly between groups.
Discussion
Results of this controlled clinical trial demonstrate that,
compared to controls, single intralesional PRP treatment
leads to an earlier reduction of the degree of lameness
until week 8 and to an earlier decrease in palpable skin
temperature of the SDFT region until week 4 after treat-
ment. At 24 weeks after PRP treatment ultrasound tissue
characterization showed a significantly higher percentage
of type II echoes which, in combination with decrease of
type III and IV, is indicative for advanced repair as the
fibrillar matrix is getting organized into fascicles,
although not yet aligned into lines of stress. Eighty per-
cent of the PRP treated horses reached their previous or
a higher level of performance after 12 months and 60 %
continued to perform at this level after 24 months com-
pared to 50 % in the CG at both time points.
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Because of the generally limited availability of
adequate patients for a controlled experimental study in
a clinical setting, horses of different ages, breeds and
types of use were included in the current study. It is
established that the potential for tendon healing is
greater in younger horses [50] and that among others
Fig. 2 B-mode ultrasonographic measurements. a Total cross sectional area of PRP- and saline treated SDFTs over time (global test: PRPG
p = 0.079, CG p = 0.999). b Total echo scores of PRP- and saline treated SDFT lesions over time (global test: PRPG and CG p < 0.001). c Fiber
alignment scores of PRP- and saline treated SDFT lesions over time (global test: PRPG and CG p < 0.001). Mean ± SE; Values labelled with asterisk
(*) differ significantly (p < 0.05) between groups. Different letters (PRP normal and control italic) indicate significant differences (p < 0.05) within
groups; PRPG = PRP-group: n = 10 limbs, SDFTs treated intralesionally with PRP; CG = control group: n = 10 limbs, SDFTs treated intralesionally with
saline; black arrow = day 0: diagnosis, intralesional injection of PRP/saline; PRP = platelet-rich plasma; FAS = fiber alignment score; SDFT = superficial
digital flexor tendon; TCSA = total cross sectional area; TES = total echo score; w =weeks
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Fig. 3 (See legend on next page.)
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male gender and high body weight are risk factors for
tendinopathy [51]. The CG contains more horses used
for show jumping and eventing which generally implies
a higher tendon load and a potentially higher risk for
self-inflicted blunt trauma than the use as e.g. dressage
horse [52]. This has a potential impact on the severity of
tendon lesions and during the long term rehabilitation
after 24 weeks.
Fiftyfive percent of the horses included in the current
study had ultrasonographic signs of marginal/peripheral
SDFT lesions which was considered as a high proportion
compared to centrally located tendon lesions frequently
diagnosed in race- and performance horses [4]. The eti-
ology of peripheral tendon lesions has not been investi-
gated separately. However, it has been assumed that
these lesions typically occur in show jumpers, dressage
horses [52] and cutting horses [53]. They may be attrib-
uted to degeneration or blunt trauma, e.g. self-kicking
with the ipsilateral hind hoof, or to excessive strain on
the lateral aspect of the affected limbs [53]. By contrast
centrally located (“core”) lesions are the result of repeti-
tive micro-injuries at high speed exercise and consecu-
tive repair with insufficient tissue [3]. This lesion pattern
was detected in only 3 horses in the current study
(See figure on previous page.)
Fig. 3 Ultrasound tissue characterization: Proportion of echo-types I-IV. Proportion of echo types a I, b II, c III and d IV for PRP and saline treated
SDFTs; PRP-group: solid lines; Control group: dotted lines; Mean ± SE; Values labelled with asterisk (*) differ significantly (p < 0.05) between groups.
Global tests: echo type I: PRPG p = 0.099, CG p = 0.004; echo type II: PRPG p = 0.204, CG p = 0.057; echo type III: PRPG p < 0.001, CG p = 0.002; echo
type IV: PRPG p < 0.001, CG p = 0.940; Different letters (PRP normal and control italic) indicate significant differences (p < 0.05) within groups;
PRPG = PRP-group: n = 10 limbs, SDFTs treated intralesionally with PRP; CG = control group: n = 10 limbs, SDFTs treated intralesionally with saline;
PRP = platelet-rich plasma; SDFT = superficial digital flexor tendon; w = weeks
Fig. 4 Ultrasound tissue characterization: Proportion of combined echo-types (a) I + II and (b) III + IV. PRP-group: solid lines; Control
group: dotted lines; Mean ± SE; Global tests: combined echo type I + II: PRPG p= 0.0826, CG p= 0.318; combined echo type I + II: PRPG p < 0.001; CG
p= 0.362; Different letters (PRP normal and control italic) indicate significant differences (p< 0.05) within groups; PRPG = PRP-group: n= 10 limbs, SDFTs
treated intralesionally with PRP; CG = control group: n= 10 limbs, SDFTs treated intralesionally with saline; PRP = platelet-rich plasma; SDFT = superficial
digital flexor tendon; w=weeks
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population which predominantly consisted of warm-
blood horses used for jumping and dressage purposes.
This might explain why the effect of a single PRP
injection on several parameters of tendon healing study
was less profound in the current than in the surgical
model used by Bosch et al. (2010) [14] that mimics cen-
tral core-lesions after single macro-trauma in young
mature horses, thus no effects of underlying ageing and/
or degeneration. A recent systematic literature review
revealed that generally more experimental, especially in
vitro PRP studies yield positive results than clinical trials
do, which proves that experimental settings only imper-
fectly replicate conditions of natural tendon repair [18].
Although the number of peripheral tendon lesions was
similar in both groups of the current study, different lesion
patterns potentially respond differently to intralesional in-
jections. Fluid might more easily reflux to the subcutis after
injection into marginally compared to centrally located le-
sions as the former are only surrounded by the peritendi-
neum at their peripheral aspect. At the same time larger
tendon lesions generally have a worse prognosis for func-
tional repair [54] and CSA of peripheral lesions is small in
most cases. It has been shown that peripheral tendon
lesions in cutting horses required a mean convalescent
period of 4 months before horses returned to full exercise
[53] which is shorter than the usual rehabilitation period
for other SDFT injuries [2].
In the current study all tendon lesions were injected
with the same volume of PRP or saline to avoid an
impact of a variable volume on the outcome. This was
practiced inconsistently in previous studies including
injections of naturally occurring, i.e. non-standardized ten-
don or ligament lesions with variable dimensions [16, 55].
A volume of 3 ml was chosen based on encouraging results
of an equine study using the same volume in an experimen-
tal model of SDFT tendinopathy [14]. Volumes used in
previous case series mostly focusing on suspensory
ligament desmopathy varied between 0.5 and 12 ml [16, 17,
19, 55]. The volume chosen in the current study seemed to
be appropriate as no resistance of the syringe plunger oc-
curred during injection of the SDFTs being slightly under
tension in a weightbearing position.
The volumes of PRP and saline were evenly distributed
to three injection sites in the current study. A compar-
able approach was chosen in a human study comparing
the effect of PRP and saline on chronic Achilles tendino-
pathy [20]. Saline led to similar improvements of the
tendon structure as PRP which might indicate that also
multiple injections with tiny volumes of sterile saline at
one single time-point may trigger a healing response.
The number of horses with owner consent for a
controlled clinical trial is generally limited and the
current study was conducted in an equine referral clinic
where horses are usually presented within several weeks
after onset of clinical signs of tendinopathy. This led to
the decision to include horses with a history of clinical
signs of tendinopathy for up to 8 weeks. It had to be ac-
cepted that some tendons were most probably already in
the late proliferative or even in the remodelling phase of
tendon healing while most were in the late inflammatory
and early proliferative phase. By contrast mechanically
induced core lesions were treated as early as 1 week
after creation of lesions, i.e. at the end of a well-defined
acute inflammatory phase in the experiment by Bosch et
al. (2011) [13]. There is evidence that timing of intrale-
sional tendon treatment has a significant influence on
outcome supported by a comparative experimental
equine investigation showing that PRP treatment 7 days
after SDFT lesion creation led to an earlier improvement
of ultrasonographic parameters than treatment on day
14 [56]. It is known that growth factors from the α-gran-
ula of platelets such as PDGF and TGF-ß have a positive
influence during the inflammatory phase of tendon heal-
ing: [57–59]. In an experimental model of rat collateral
ligament injury the effectiveness of PDGF dropped
markedly if it was administered more than 24 h after in-
jury [60]. This is in accordance with results after treat-
ment of chronic human Achilles tendinopathy which
showed no beneficial effects of PRP versus placebo treat-
ment with sterile saline [20]. At the same time PRP in-
jections have been reported to be beneficial in chronic
human tendon disorders refractory to other treatment
modalities in several uncontrolled clinical studies [23,
61]. During the proliferation and remodelling phase of
tendon healing Vascular Endothelial Growth Factor,
which is a major component of PRP, might play a role as
promotor of angiogenesis [58].
Horses in the current study received a single PRP
treatment. This decision was based on the finding that
growth factor and cytokine release from platelets
continues from their mRNA reserves for at least 7 days
after activation [62] and on a significant and long-lasting
effect of a single injection approach in an experimental
equine tendinopathy study [14]. Another reason was the
intention to investigate a low dose of PRP as a basis for
further research in equine naturally occurring
tendinopathies [33], because to date no dose dependent
studies are available with regard to treatment of equine
tendinopathies. The limited long term effect in the
current study may have been influenced by the fact that
most growth factors contained in PRP are per se short
lived which probably contributed to a low concentration
over time in the clinical setting chosen. In a study using
a rodent experimental model it was also shown that a
single injection of heterologous PRP immediately after
Achilles tendon transection only had time-limited effects
on tendon healing during the observation period of up
to 6 weeks [63]. Results of another experimental study
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in a rodent model of tendinosis suggested that a single
intratendinous injection of PRP does not lead to a local
and systemic increase in several cytokines and growth
factors over the observation period of 25 days [64].
The adequate number of injections over time is also a
point of debate in naturally occurring human tendinopa-
thy: In a long term clinical trial in humans it was shown
that a second early PRP injection does not rapidly
improve clinical signs of tendinopathy in case of incom-
plete resolution after the first treatment [65]. However,
it has been shown in a controlled human clinical trial
that patients with chronic patellar tendinopathy
receiving two injections of a leucocyte poor platelet
concentrate (autologous conditioned plasma®) showed
better improvement in outcomes when compared to a
monoinjection [66]. Accordingly application of 3 consecu-
tive PRP injections significantly improved clinical symp-
toms and function of human athletes with chronic patellar
tendinopathy [22]. Summarily it cannot be excluded that
more than one intralesional treatment might have en-
hanced the clinical effects observed in the current study.
Based on whole blood platelets and leucocytes were
concentrated by a mean factor of 5.67 and 1.81, respect-
ively in PRP in the current study. Compared to other
PRP systems the bag system used in this study leads to
an intermediate platelet and low leucocyte concentration
[24]. By contrast platelets and leucocytes were enriched
with factors 3.78 and 6, respectively, utilizing a different
double centrifugation system in an equine surgical
model of tendinopathy [14]. Among various other
factors the different concentrations of platelets and
leucocytes might have contributed to the differences in
outcome between the latter and the current study.
Low platelet counts have been demonstrated to be
inefficient in bone regeneration [67] and increasing
platelet concentrations in a leucocyte reduced PRP prep-
aration leads to delivery of more anabolic and less pro-
inflammatory cytokines in vitro [28]. However, with
increasing platelet concentrations the synthesis of
collagen type I and III decreases suggesting a diminish-
ing effect on tendon metabolism [28]. This observation
corresponds to a dose dependent in vitro investigation
showing that intermediate platelet concentrations, such
as used in the current study, have stronger effects on
tenocyte proliferation, migration and collagen produc-
tion than highest concentrations [68].
While some beneficial effects such as anti-infectious
properties [69], growth factor content [70] and promo-
tion of chemotaxis, proliferation and differentiation of
cells [71] have been attributed to leucocytes they also
contribute to a greater acute inflammatory response [29,
72] and to the expression of catabolic factors, e.g. MMPs
and IL-1, that may influence tendon healing negatively
[27, 73, 74], so that a low leucocyte content seems to be
preferable to enhance anabolic effects during tendon
healing.
In summary PRP characteristics vary significantly de-
pending on the technique and preparation kit used for
its production [24, 75] which has a significant impact on
clinical outcome and makes comparison between clinical
trials difficult [61]. The optimal platelet to leucocyte
ratio for treatment of tendinopathy is unknown to date
and most probably dependent on the stage of tendon
healing [76].
Clinical parameters did not differ between the PRPG
and controls at any time point which corresponds to the
results of an equine PRP study using an experimental
model of tendinopathy [14]. However, clinical signs of
inflammation such as the degree of lameness and scores
for skin surface temperature decreased earlier in the
PRPG than in the CG which may be attributed to anti-
inflammatory and analgesic effects of PRP [40, 77, 78].
This correlates well to reduced pain scores in humans
after PRP treatment of tendinopathy [79, 80] and to un-
controlled observations in two horses that returned to
competition level performance as soon as 4,5 months
after PRP treatment of SDFT lesions [17]. However,
mean scores for sensitivity to palpation decreased earlier
in controls than in PRP treated tendons despite a similar
curve progression in both groups. This is potentially
attributed to a high interindividual variation of score
values due to the inclusion of different lesion patterns.
Established semi-quantitative clinical score systems were
used to monitor clinical parameters in the current study.
Accuracy could have been increased by the use of
computerized gait analysis and thermography [81].
With regard to B-mode ultrasonography total cross
sectional area (T-CSA) decreased significantly between
week 4 and 18 after PRP treatment while it did not
change throughout the observation period in the CG.
Sensitivity of CSA is potentially low to detect minor
changes as shown by routine ultrasound assessment of
racehorses [82]. However, a delayed decrease of T-CSA
after the inflammatory phase of tendon healing can be
interpreted as a therapeutic effect of the PRP injection.
In contrast to controls, scores for echogenicity were
significantly higher which implies a low echogenicity of
the tendon lesions at 4, 8 and 12 weeks after PRP treat-
ment and at week 24, i.e. at the end of the observation
period. Similarly scores for fiber alignment were signifi-
cantly higher in the PRPG than in the CG at 4, 8 and
12 weeks after treatment suggesting a lower degree of
continuity of fibrous structures. A potential explanation
for the differences between groups is that TES and FAS
as determined by B-mode were higher in the PRP group
from the beginning of the experiment onwards, as com-
parison of the different time points reveals a tendency to
a significant difference (p = 0.05−0.1) for most of the
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remaining time points. Consequently the intermittent
significant difference between groups should be inter-
preted with caution. However, it cannot be excluded that
PRP injection effectively induced a transient inflamma-
tory response [29, 83] which might have contributed to
a temporary decrease in echogenicity and in alignment
of fibrous structures. This contrasts with results of an
experimental equine study showing no differences at all
for several B-mode parameters between SDFTs treated
with a leucocyte poor single centrifugation plasma prod-
uct and saline [84]. Although echogenicity and fiber
alignment scoring using B-mode ultrasonograms are
established tools in clinical settings, they have a limited
sensitivity to adequately reflect tendon intergrity [35].
Additionally lesion types included in the current study
were heterogenous and the number of cases per group
was relatively low. These factors made B-mode ultrason-
ography not the ideal modality to comparatively monitor
especially subtle changes during the process of tendon
repair in the current study. It could be proved that echo-
genicity and fibre alignment scores based on B-mode
ultrasonograms do not correspond to the degree of echo
continuity as determined by UTC implying a higher sen-
sitivity of the latter technique [35, 37].
During ultrasound tissue characterization of PRPG
tendons there was a significant drop in the proportion of
non-structure related echo-type type IV representing a
mainly amorphous matrix and/or free fluid between day
0 and week 12 while proportions for this echo type
remained on the same level in the CG throughout
24 weeks. This phenomenon was previously observed in
an experimental equine study after a single PRP injec-
tion and may be attributed to acute anti-inflammatory
effects exerted by PRP [40, 77, 78].
The decreasing proportions of non-structure related
echo types III and IV between day 0 and week 12 after
PRP treatment in the current study rather resembles the
course between week 4 and 12 after surgical induction
of SDFT lesions without treatment [39] and the progres-
sion between week 5 and 18 after PRP treatment in
another experimental equine study [40] and might there-
fore be an indicator for the chronicity of some tendon
lesions included in the current study population. Hence,
the delayed treatment up to 8 weeks after the onset of
clinical signs might have contributed to a right-shift of
the healing pattern as determined by UTC compared to
experimental tendon lesions. However, more frequent
UTC examinations between day 0 and week 12 would
have been necessary to further prove this. This could
not be realized due financial constraints and organisa-
tory reasons as all horses were client owned and horses
have to be sedated for 30–60 min during UTC scanning.
Between week 12 and week 24 combined echo-types I
and II (fascicular structures) increased significantly
within the PRPG. This resulted in a significantly higher
percentage of echo type II being representative for the
organization of a fibrillary matrix into fascicles that are
still discontinous and not yet aligned, thus still remodel-
ling after 24 weeks in PRP treated compared to control
tendons. An echo-type II ratio described for normal
tendon tissue, i.e. approximately 0.18 [39], was almost
reached. In combination with a significant decreases of
summarized echo-types III and IV between week 12 and
week 24 this indicates an advanced organization of fibril-
lar and amorphous matrix into fascicles that are less
continuous, more swollen and not aligned yet. The latter
interpretation is supported by a lack of significant
differences between groups with regard to echo-type I
proportions representing intact and fully aligned
fascicles (secondary tendon bundles).
In contrast to the current study PRP treated SDFTs had
a significantly lower percentage of echo type II than con-
trols in a surgical tendon model at the end of the observa-
tion period of 24 weeks [40]. This indicates that in the
Bosch et al. study, using a single macro-trauma, the PRP-
treated tendons passed already the remodelling stage
while during the experiment described in this manuscript
the fascicles were still not aligned yet and still requiring
remodelling. In general the higher proportion of echo-
type II in the PRPG is an indicator of an active process of
remodelling 24 weeks after treatment [40].
The proportion of echo type III being representative for
mainly fibrillar matrix continued to decrease significantly
between week 12 and 24 only in the PRPG. Comparison
of the proportion of this echo type to others in the PRPG
suggests that the decrease in echo type III is rather in
favour of echo type I than in favour of echo type II be-
tween week 12 and 24 as could be expected from a previ-
ous study [39]. Main reason for this observation is that in
our study there are only limited time-points for UTC
scanning, missing some detailed information on stages of
repair. Anyhow, this finding suggests a transformation
from fibrillar components into intact and aligned tendon
bundles during the remodelling phase after PRP treatment
of naturally occurring tendinopathies.
All horses included in the current study underwent
the same controlled exercise regimen as it is known
that controlled exercise has a therapeutic effect on
tendon healing [85]. The duration of the controlled
exercise prescribed for the included horses started on
the basis of the estimated duration of tendinopathy
(<4 weeks or 5–8 weeks) to adequately address the
potentially therapeutic effect of gradually increasing
controlled exercise on the process of tendon healing
in each individual. To avoid inadequate loading of the
tendons immediately after treatment all horses were
given 3 days box rest and the first actual exercise
level was restricted to 10 min walk.
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Similarly all horses were shod with a closed horse shoe
with a straight bar because this type of shoeing has been
described as adequate during rehabilitation in cases of
SDFT tendinopathy [49]. Despite potential alternative ap-
proaches to decrease strain in the SDFT via orthopaedic
shoeing [86] authors intended to assure that rehabilitation
conditions including shoeing were as similar as possible
for all horses which seemed to be achievable most consist-
ently with the type of shoeing chosen.
Recurrence rate is one of the most critical parameters
of long-term functionality after tendon injury [31]. Only
1 out of 10 horses in either group developed recurrence
of tendinopathy in the treated limb within 24 months
after treatment. This is a lower recurrence rate than that
previously reported after conventional intralesional
treatment of SDF tendinopathy in different types of per-
formance horses [2]. However, it has to be considered
that several previous equine tendon studies mainly
included racehorses typically developing centrally
located core lesions [3, 31] which probably have a differ-
ent etiology than most of the tendon lesions in the
current study [53]. Due to the relatively low number of
horses included and different types of use, recurrence
rate in the current study should be interpreted cau-
tiously. Biomechanical testing using tendon explants is
the gold standard to determine elasticity and strength of
tendon tissue. Due to the inclusion of client owned
horses it could not be performed in the current study.
The performance level which is another important
indicator of functionality did not differ statistically
between groups at 12 and 24 months after treatment.
However, the current study revealed that 8 versus 5
horses reached their previous level of performance
12 months after PRP and saline treatment respectively.
After another 12 months only 6 of the PRP treated and
5 control horses performed at their previous level. This
finding reflects the results of a clinical study including
racehorses with midbody suspensory ligament demopa-
thies [16]. Horses treated with PRP had fewer starts than
control horses delayed only during the third year after
return to racing.
Conclusions
This controlled clinical trial shows that a single intrale-
sional injection of PRP up to 8 weeks after onset of
clinical signs of tendinopathy contributes to an earlier
reduction of lameness compared to a single intralesional
treatment with saline. Compared to controls fibrillar
matrix in PRP treated tendons is getting organized into
fascicles that are not aligned yet after six months which
is a sign of advanced tendon repair while remodelling
continues. PRP treatment has the potential to increase
the number of horses reaching their previous or a higher
level of performance after 12 months which is not
sustained after 24 months. Earlier treatment of tendino-
pathy with PRP should be considered to enhance these
effects. Future controlled clinical studies should include
higher numbers of horses.
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